Hyderabad, India
MSN Laboratories is a rapidly growing, research-based pharmaceutical company headquartered in Hyderabad, India. Established in 2003, the company's mission is to provide high-quality medicines at affordable prices, with a focus on accessibility. With 22 state-of-the-art manufacturing facilities in India and the USA, including 15 API and 7 Finished Dosage Facilities, MSN is well-positioned for global reach.
The company's integrated R&D centre plays a key role in its success, allowing for innovation and the rapid introduction of new, cost-effective therapies to the global market. With a product portfolio comprising 450+ APIs and 300+ Finished Dosages, MSN Laboratories covers over 35 major therapeutic offerings, including Oncology, Cardiology, CNS, Diabetes, Nephrology, Urology, Gastroenterology, and Orthopaedics.
MSN Laboratories has filed 900+ national and international patent applications, positioning itself as a leader in innovation and quality. Additionally, with a track record of trust from 40 million patients across 100+ countries, MSN has demonstrated its global impact.
The company's exponential growth, from $22 million USD in 2005 to achieving a turnover of approximately $670 million USD in FY 2021-22, underscores its success and potential. MSN Laboratories' proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight-driven IT, and world-class facilities are the driving forces behind this growth.
With a dedicated team of over 14,000 qualified professionals, MSN Labs remains committed to bringing integrity, imagination, and innovation to the forefront of its operations. As a vital player in the Biotechnology and Health Care industries, MSN Laboratories continues to expand its global footprint by creating innovative solutions to meet tomorrow's healthcare needs.
